"10.1371_journal.pone.0029066","plos one","2012-01-04T00:00:00Z","Dag E Nilssen; Per Brandtzaeg","Laboratory for Immunohistochemistry and Immunopathology (LIIPAT), Centre for Immune Regulation (CIR), University of Oslo, and Department of Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Department of Medicine, Akershus University Hospital, Lørenskog, Norway","Conceived and designed the experiments: DEN PB. Performed the experiments: DEN. Analyzed the data: DEN. Contributed reagents/materials/analysis tools: DEN PB. Wrote the paper: DEN PB.","Medinnova is a limited company owned by Oslo University Hospital and was recently merged with a similar service unit of the University of Oslo into a new company named Inven2. As of January 1, 2011, the two service units are co-located at Gaustadalléen 21, Oslo, Norway in Oslo Innovation Center. Medinnova continues to deliver competitive services adapted for biomedical research environment needs for health enterprises, hospitals, universities and colleges or individuals. It manages all categories of research collaboration and promotes clinical research, laboratory research and animal experimental studies. Medinnova thus contributes to high-quality research and acts in accordance with agreements. Support of the authors study from Medinnova and any other source does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","01","Dag E Nilssen","DEN",2,TRUE,2,1,1,2,TRUE,TRUE,FALSE,0,NA,FALSE
